Tirzepatide

Tirzepatide - GLP-1 / GIP Dual Agonist Research Peptide

Tirzepatide is a synthetic research peptide developed by Eli Lilly that activates two different gut-hormone receptors at once: GLP-1 (the same receptor semaglutide hits, behind Ozempic and Wegovy) and GIP (glucose-dependent insulinotropic polypeptide). It’s the active molecule in Mounjaro and Zepbound and was the first dual incretin agonist engineered for once-weekly administration. Because it adds GIP to the GLP-1 mechanism that semaglutide already established, tirzepatide is the most common reference compound for dual-agonist research and the direct precursor to Lilly’s triple agonist, retatrutide.

Why Dual Agonism Matters

GLP-1 on its own addresses only half of the gut-hormone signal the body releases after a meal. GIP contributes the other half: it amplifies insulin secretion, acts on adipose (fat) tissue, and appears to reduce some of the nausea signaling that comes from GLP-1 in isolation. By combining both receptor activities in a single molecule, tirzepatide lets researchers study the two signals together rather than running them as separate experiments.

Tirzepatide vs Semaglutide vs Retatrutide

All three peptides come from the same GLP-1 research lineage but target different receptor combinations.

The practical research distinction: tirzepatide added GIP to what semaglutide was already doing, and retatrutide added glucagon on top of that. Direct head-to-head data (SURMOUNT-5, published 2024) showed tirzepatide produced larger body-composition endpoints than semaglutide over 72 weeks.

Aplicaciones de investigación

Tirzepatide is used in studies examining:

• Body-composition changes under sustained dual-incretin stimulation
• How the added GIP signal changes glucose and insulin dynamics relative to GLP-1-only agonists
• Appetite and satiety models
• Cardiovascular and metabolic markers in the SURMOUNT and SURPASS trial frameworks
• Dose-response characterization across published trial doses (5, 10, 15mg)
• Reference comparisons against semaglutide (single agonist) and retatrutide (triple agonist)

Especificaciones

Storage & Handling

Unopened vials are kept at 2-8°C under standard cold-chain conditions and remain stable for 12+ months. Reconstitution parameters, solvent compatibility, and post-reconstitution stability for Tirzepatide are documented in the published peer-reviewed literature and standard peptide-chemistry references.

Reference Literature

Published clinical and preclinical Tirzepatide literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.

Common Questions About Tirzepatide Research

Is tirzepatide the same as Ozempic?

No. Ozempic’s active ingredient is semaglutide, which activates one receptor (GLP-1). Tirzepatide activates two receptors (GLP-1 and GIP) and is the active ingredient in Mounjaro and Zepbound. They come from different manufacturers - semaglutide from Eli Lilly.

What is the difference between tirzepatide and retatrutide?

Tirzepatide activates GLP-1 and GIP. Retatrutide activates those same two receptors plus glucagon, making it a triple agonist. Retatrutide is still in Phase 3 clinical trials; tirzepatide is already commercialized as Mounjaro and Zepbound. In terms of published outcomes, retatrutide has reported larger body-composition endpoints in Phase 2 than tirzepatide has in equivalent-length studies, though direct head-to-head trials are still ongoing.

What does tirzepatide do in metabolic studies?

It activates GLP-1 and GIP receptors simultaneously. Together these receptors regulate glucose-dependent insulin release, glucagon suppression, gastric emptying, appetite signaling in the hypothalamus, and adipose-tissue metabolism. Study endpoints most commonly tracked are HbA1c, fasting glucose, body composition, and ad-libitum caloric intake.

Is tirzepatide FDA approved?

The brand-name formulations (Mounjaro for type 2 diabetes, Zepbound for weight management) are FDA approved for specific clinical indications. Research-grade tirzepatide sold by WWP is not a branded drug product and is not approved or intended for human consumption. Every vial is labeled and sold strictly for laboratory and research use only.

How is tirzepatide stored?

Unopened vials are stored at 2-8°C (refrigerator temperature) and stay stable for 12+ months. Once reconstituted with bacteriostatic water, the solution is kept at 2-8°C and used within 28-30 days.

Garantía de pureza

Cada lote tiene una pureza ≥99 %. Envíanos un certificado de análisis (COA) de cualquier análisis independiente y te daremos un vale de compra, independientemente de lo que indique.